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ABSTRACT
BM742401 is a tumor suppressor lncRNA downregulated in gastric cancer. As the 
promoter region and the entire transcript are embedded in a CpG island, we postulated 
that BM742401 is a tumor suppressor lncRNA inactivated by DNA methylation in 
chronic lymphocytic leukemia (CLL). The promoter of BM742401 was unmethylated 
in normal controls including three each of normal bone marrow, peripheral blood 
buffy coats, and CD19-sorted peripheral B-cells, but methylated in four (57.1%) 
CLL cell lines. Methylation of BM742401 correlated inversely with expression. In the 
completely methylated WAC3CD5+ CLL cells, 5-Aza-2ʹ-deoxycytidine treatment led 
to promoter demethylation and re-expression of BM742401 transcript. Functionally, 
stable overexpression of BM742401 resulted in inhibition of cellular proliferation 
and enhanced apoptosis through caspase-9-dependent intrinsic but not caspase-
8-dependent extrinsic apoptosis pathway, suggesting a tumor suppressor role of 
BM742401 in CLL. In primary CLL samples, methylation of BM742401 was detected 
in 43/98 (43.9%) of patients. Moreover, among CLL patients with standard-risk 
cytogenetic aberrations, methylation of BM742401 correlated with advanced Rai 
stage (≥ stage 2)(P = 0.002). Furthermore, BM742401 methylation was associated 
with miR-129-2 methylation (P = 0.05). BM742401 is a tumor suppressor lncRNA 
frequently methylated in CLL. The mechanism of BM742401 as a tumor suppressor 
warrants further studies.
INTRODUCTION 
DNA methylation refers to the addition of a methyl 
group (−CH3) to the carbon 5 position of the cytosine 
ring in a CpG dinucleotide, leading to the formation of 
5-methylcytosine [1]. Global DNA hypomethylation but 
aberrant DNA hypermethylation of tumor suppressor 
genes (TSGs) is a hallmark of many human cancers [2]. 
To date, in hematological cancers, methylation-mediated 
silencing of multiple TSGs have been found involved in 
the dysregulation of multiple cellular pathways including 
CDKN2A and CDKN2B in the regulation of cell-cycle, 
DAPK1 and APAF1 in the regulation of apoptosis, and 
soluble WNT inhibitors involved in inhibition of WNT 
signaling [3–6]. Of note, methylation-mediated silencing 
of both protein-coding TSGs, including DAPK1, ID4 and 
SFRP1, and tumor suppressor miRNAs, including miR-9-3, 
miR-34b/c, miR-129-2, miR-203 and miR-3151, have been 
implicated in CLL leukemogenesis or prognosis [7–13].
Long non-coding RNA (lncRNA) is defined as a 
novel class of RNAs longer than 200 nucleotides with 
little or no protein-coding capacity. It can be further be 
categorized into five subgroups, including intergenic, 
intragenic, natural antisense transcripts, pseudogenes and 
unclassified transcripts, based on the location relative 
to annotated protein-coding genes (PCGs) [14, 15]. 
Moreover, lncRNAs are known to activate or inhibit gene 
expression involved in multiple biological processes 
through epigenetic, transcriptional or post-transcriptional 
mechanisms [16, 17]. 
In addition to PCGs and miRNAs, lncRNAs are 
found dysregulated in many human cancers, indicating 
their potential oncogenic or tumor suppressor role in 
carcinogenesis [15]. For example, HOX transcript 
antisense intergenic RNA (HOTAIR) is found 
overexpressed in breast cancer, in particular in patients 
with metastasis, suggestive of an oncogenic role in cancer 
metastasis [18]. Conversely, maternally expressed gene 
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3 (MEG3) is a tumor suppressor lncRNA downregulated 
in multiple human cancers, inhibiting cell proliferation 
through accumulation of TP53 protein by abrogating 
MDM2 function [19, 20]. Intriguingly, the promoter-
associated CpG island of MEG3 was found frequently 
hypermethylated in both solid and hematological 
malignancies, indicating that methylation-mediated 
silencing may serve as an alternative mechanism for 
inactivation of tumor suppressive lncRNAs [19]. 
In CLL, deletion of chromosome 13q14 is the 
most frequent chromosomal alteration detected in 
approximately 60% newly diagnosed patients, portending 
superior survivals [21]. In addition to miR-15a/16-1 
cluster, a lncRNA, DLEU2 was found co-deleted in the 
minimally deleted region (DMR) of del(13q14), hence 
implicating a potential tumor suppressor role of DLEU2. 
Interestingly, downregulation of DLEU2 in CLL has 
recently been ascribed to DNA methylation of its CpG 
islands [22]. Moreover, long intergenic non-coding 
RNA p21 (lincRNA-p21) and nuclear enriched abundant 
transcript 1 (NEAT1) were identified as transcriptional 
targets of TP53 and implicated in the TP53-depedent 
cell death after DNA damage in CLL [23]. However, 
apart from DLEU2, lincRNA-21 and NEAT1, the role of 
lncRNAs in CLL remains unexplored. 
Recently, BM742401 has been found to be a tumor 
suppressor lncRNA inhibiting metastasis, and repression 
of BM742401 was associated with inferior survivals in 
patients with gastric cancer [24]. Moreover, restoration 
of BM742401 resulted in inhibition of metastasis and 
decreased secretion of extracellular MMP9, which 
enhances cell migration and invasion. As the promoter 
region and the entire transcript of BM742401 are 
embedded in a CpG island, and the fact that methylation 
may serve as an alternative mechanism for silencing 
of tumor suppressor lncRNAs; herein, we postulated 
BM742401 is a tumor suppressor lncRNA inactivated by 
DNA methylation in CLL.
RESULTS
Methylation of BM742401
Normal controls
 As illustrated in the schematic diagram showing the 
putative promoter region of BM742401 (Supplementary 
Figure S1), methylation of BM742401 was studied by MSP 
and pyrosequencing by primers designed upstream to the 
transcription start site. The promoter of BM742401 was 
completely unmethylated in all of the nine normal controls 
(N1 to N9), but completely methylated in the positive 
control DNA (Figure 1A). Direct sequencing analysis of 
the M-MSP products amplified from the positive control 
showed expected conversion of unmethylated cytosine, but 
not methylated cytosine, into thymidine, indicating complete 
bisulfite conversion and specificity of the MSP (Figure 1B). 
CLL cell lines
 In CLL cell lines, M-/U-MSP analysis showed 
that the promoter of BM742401 was completely 
methylated (MM) in MEC1, I83-E95 and WAC3CD5+, 
partially methylated (MU) in HG3, and completely 
unmethylated (UU) in MEC2, 232B4, and CLL-AAT 
(Figure 1C). Moreover, the MSP methylation statuses 
MM, MU, and UU were confirmed by quantitative 
bisulfite pyrosequencing (Figure 1D). Together, these data 
suggested that methylation of BM742401 was absent in 
normal controls but detected in four (57.1%) CLL cell 
lines, and hence tumor-specific.
Primary CLL samples at diagnosis
By MSP, methylation of BM742401 was detected 
in 43/98 (43.9%) of diagnostic CLL marrow samples 
(Figure 1E). Methylation of BM742401 is found 
significantly associated with older age and higher 
diagnostic lymphocyte count (Supplementary Table S1). 
The mean age of patients with and without methylation 
of BM742401 were 69 and 64 years old respectively 
(P = 0.03; Supplementary Table S1). The mean diagnostic 
lymphocyte count of patients with and without methylation 
of BM742401 were 29 × 109/L and 64 × 109/L respectively 
(P = 0.04; Supplementary Table S1). However, there was 
no association between the methylation of BM742401 and 
diagnostic hemoglobin level, platelet count, Rai stage, 
gender, death or high-risk karyotypes (Supplementary 
Table S1). The median OS of CLL patients with and 
without methylation of BM742401 were 97 and 94 
months respectively (P = 0.85; Supplementary Table S1). 
Moreover, among 44 low-risk CLL patients with 
del(13q14), normal karyotype or other karyotypic changes, 
methylation of BM742401 significantly correlated with 
advanced Rai stage (≥ stage 2) (P = 0.002), but not 
survival. In addition, in 51 CLL patients with concomitant 
methylation study for both BM742401 and miR-129-2, 
methylation of BM742401 was significantly associated 
with that of miR-129-2 (P = 0.05).
Methylation and expression of BM742401 in 
CLL cells
In CLL cell lines
CLL cell lines methylated for BM742401 were 
significantly associated with lower expression of 
BM742401, as evidenced by RT-qPCR showing a higher 
∆Ct (Ct BM742401– Ct GAPDH), than those CLL cell 
lines completely unmethylated for BM742401 (P = 0.032) 
(Figure 2A). 
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5-AzadC treatment of WAC3CD5+ cells 
In WAC3CD5+ cells, which were completely 
methylated for BM742401, hypomethylation treatment 
with 5-AzadC led to the demethylation of BM742401 
promoter, as evidenced by the emergence of the U-MSP 
signal (Figure 2B) and decrease of the mean methylation 
percentage along the promoter CpG dinucleotides 
(Figure 2C) on day 5. Simultaneously, upon 5-AzadC 
treatment, expression of BM742401 was increased in 
WAC3CD5+ cells (Figure 2D).
Potential interplay between BM742401 with 
neighboring GATA6 
While lncRNA may regulate the expression of its 
neighboring gene [25], whether methylation-mediated 
silencing of BM742401 is linked to its neighboring 
protein-coding gene GATA6 was studied in CLL cell lines 
by qRT-PCR. Results showed that GATA6 had a trend 
of lower expression in BM742401-methylated cell lines 
(MEC1, I83-E95 and WAC3CD5, HG3) than BM742401-
unmethylated cell lines (MEC2, 232B4, and CLL-AAT) 
Figure 1: Methylation of BM742401. (A) Methylation-specific PCR (MSP) showed that BM742401 was completely unmethylated 
in normal controls. (B) Sequencing analysis of the M-MSP product from a methylated positive control showed the expected conversion of 
unmethylated cytosine to uracil (turned into thymidine after PCR) while leaving methylated cytosine unchanged, indicating the complete 
bisulfite conversion and specificity of MSP. The unmethylated cytosine was visualized by underlined text while the methylated cytosines 
highlighted in red. (C) MSP showed the methylation status of BM742401 in a panel of CLL cell lines. (D) Pyrograms of quantitative 
bisulfite pyrosequencing showed the methylation intensity on a stretch of 7 neighboring CpG dinucleotides of BM742401 in normal 
control, 50% methylation control, positive control with methylated DNA and CLL cell lines with defined MSP methylation status, complete 
methylation (MM), partial methylation (MU) and unmethylation (UU). (E) MSP showed BM742401 methylation in primary CLL samples.
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(P = 0.14) (Supplementary Figure S2), as indicated by 
a higher ∆Ct (Ct GATA6 − Ct GAPDH) in BM742401-
methylated than BM742401-unmethylated CLL cell lines. 
Function of BM742401 in CLL cells  
As BM742401 was frequently methylated in CLL 
cells, with repressed expression, we postulated that it 
might act as a tumor suppressive lncRNA. The tumor 
suppressor function of BM742401 was studied by stable 
overexpression of BM742401 in WAC3CD5+ CLL cells 
completely methylated for BM742401 via lentiviral 
transduction (Figure 3B). By RT-qPCR, BM742401 was 
confirmed to be overexpressed in WAC3CD5+ cells, as 
compared with WAC3CD5+ cells stably transduced with 
empty vector (Figure 3C). Moreover, over-expression 
of BM742401 resulted in 34% reduction of cellular 
proliferation by MTT assay (P = 0.02, Figure 3D and 
Supplementary Figure S3A) and 13% increase of dead cells 
by Trypan blue exclusion assay (P = 0.0001, Figure 3E), 
as well as 11% increase of apoptotic cells indicated by 
cells in sub-G1 phase using propidium iodide (PI) staining 
(P = 0.005, Supplementary Figure S4A and S4B), 
indicating that BM742401 is a tumor suppressor in CLL 
cells. Furthermore, restoration of BM742401 led to increase 
of the activated, cleaved Caspase 9 and cleaved Caspase 3 
(Figure 3F and 3G), but not cleaved Caspase 8 (p43/p41) 
(data not shown). Moreover, treatment with Z-LEHD-
FMK, a caspase 9 inhibitor, rescued the percentage of dead 
cells by 9% in BM742401-overexpressing cells (P = 0.012, 
Supplementary Figure S3), but not in cells with empty 
vector, confirming the tumor suppressive role of BM742401 
is mediated by the intrinsic, Caspase-9 dependent apoptotic 
pathway.
Figure 2: Methylation and expression of BM742401 in CLL cells. (A) Quantitative SYBR Green RT-PCR showed inverse 
correlation between BM742401 methylation and expression in CLL cell lines. Sequencing analysis of the SYBR Green real-time RT-PCR 
products for the detection of BM742401. Treatment of CLL cells completely methylated for BM742401 with 5-AzadC, a hypomethylating 
agent, (B) methylation-specific PCR and (C) quantitative bisulfite pyrosequencing showed BM742401 was demethylated, and 
(D) quantitative RT-qPCR revealed BM742401 was re-expressed.
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Figure 3: Function of BM742401 in CLL cells. Stable overexpression of BM742401 in WAC3CD5+ CLL cells was performed 
by lentiviral infection of a GFP-expressing plasmid cloned with full-length BM742401 cDNA. WAC3CD5+ CLL cells stably transduced 
with GFP-expressing empty plasmid were used as control. (A) Sequence analysis of GFP-expressing plasmid cloned with full-
length BM742401 cDNA. (B) Representative fluorescence (upper, 40× magnification) and bright field images (lower, 40× magnification) of 
WAC3CD5+ CLL cells stably transfected with empty vector or BM742401 are shown. (C) Quantitative RT-qPCR for BM742401 expression 
was performed. ∆Ct, Ct BM742401-Ct GAPDH. GAPDH was chosen as reference using the 2−∆∆CT method. (D) Relative cell proliferation 
of CLL cells upon over-expression of BM742401 was measured by MTT assay. (E) Percentage of dead cells was measured by Trypan blue 
exclusion assay. Data of MTT and Trypan blue assay shown were mean ± S.D. obtained from experiments in triplicate. Western blot analysis 
of (F) Caspase 9 and (G) Caspase 3 after BM742401 overexpression. Total protein was extracted the same time after lentiviral transfection 
and membranes were probed with antibodies to anti-Caspase 3, -Caspase 9 and anti-actin. Signal from anti-actin antibody was used as the 
endogenous normalizer. The numbers above the bands indicated the relative protein expression measured by densitometric analysis.
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To further confirm the tumor suppressor function of 
BM742401, the expression of BM742401 in 232B4 cells, 
which were completely unmethylated for BM742401, 
was knockdowned by transfection of BM742401-
specific 2′-O-Methyl phosphorothioate antisense 
oligonucleotides (2′OMe-PS ASOs). Upon transfection 
of BM742401-specific ASO1 and ASO2, the expression 
of BM742401 was reduced by 56% and 66% respectively 
(Supplementary Figure S5A). Moreover, knockdown by 
BM742401-specific ASO1 led to 19.9% increase of cell 
proliferation by MTT assay (P = 0.04) (Supplementary 
Figure S5B) and 6% decrease of dead cells by Trypan blue 
exclusion assay (P = 0.03) (Supplementary Figure S5C), 
as compared with non-targeting control ASO. 
Furthermore, BM742401-specific ASO2-mediated 
depletion of BM742401 led to 8% decrease of dead cells 
by Trypan blue exclusion assay (P = 0.03) compared with 
non-targeting control ASO (Supplementary Figure S5C).
DISCUSSION 
Several observations were made in this study.
First, this is the first study demonstrating tumor-specific 
methylation of BM742401 in CLL as shown by frequent 
methylation in CLL cell lines and primary CLL samples 
but not normal controls including normal CD19-sorted 
peripheral B-cells. Moreover, BM742401 expression 
in CLL cell lines inversely correlated with methylation 
status. Furthermore, hypomethylating treatment in 
completely methylated CLL cells led to demethylation 
and re-expression of BM742401. Hence, methylation 
of BM742401 promoter is associated with reversible 
silencing in CLL. 
In addition to its frequent methylation in cell lines, 
BM742401 was frequently methylated in primary CLL 
samples at diagnosis. Interestingly, there was a significant 
association of BM742401 methylation with higher 
lymphocyte counts. Despite the lack of association between 
BM742401 methylation and survival in CLL patients with 
low-risk cytogenetic aberrations, BM742401 methylation 
correlated with the advanced Rai stage (≥ stage 2), which 
is a poor prognostic factor for CLL. Given the limited 
number of samples in our cohort, the prognostic impact of 
BM742401 methylation in CLL warrants further studies. In 
light of the frequent methylation of BM742401 methylation 
in primary CLL cells, BM742401 methylation is important 
in CLL leukemogenesis. This contrasted with the frequent 
methylation of miR-124-1 in myeloma cell lines but not 
primary myeloma plasma cells, hence excluding its role in 
pathogenesis of clinical myeloma [26]. 
Secondly, to gain insight into its biological function, 
BM742401 was stably re-expressed in WAC3CD5+ 
cells with complete methylation of BM742401, which 
led to inhibition of cellular proliferation and enhanced 
cell apoptosis, indicating a tumor suppressive role in 
CLL. Caspases, a family of aspartate-specific cysteine 
proteases, are crucial mediators of apoptosis [27]. Cellular 
apoptosis may be activated by extrinsic/death receptor 
pathway or intrinsic/mitochondrial pathway [27]. In the 
extrinsic pathway, apoptosis is triggered upon activation 
of Caspase 8 upon ligation of membrane death receptors, 
such as members of the tumor necrosis factor (TNF) 
superfamily or Fas [28]. On the other hand, intrinsic 
apoptosis is triggered by the activation of Caspase 9 upon 
mitochondrial release of cytochrome C, resulting in the 
formation of apoptosome comprising  Apaf-1, Caspase 9 
and cytochrome C in the cytoplasm [29]. Once apoptosis 
is triggered, whether by extrinsic or intrinsic mechanism, 
both Caspase 8 and Caspase 9 leads to cleavage and hence 
activation of the effector Caspase 3 to initiate activation 
of the caspase cascade [30]. Herein, overexpression of 
BM742401 resulted in the activation of Caspase 9 and 
Caspase 3, but not Caspase 8, showing that the tumor 
suppressive function of BM742401 in CLL was mediated 
by activation of intrinsic apoptosis pathway.
Thirdly, BM742401 gene exists in an antisense 
orientation to a neighboring protein-coding gene GATA6. 
Moreover, in CLL cell lines, methylation-mediated 
silencing of BM742401 was linked to a lower expression 
of its neighboring protein-coding gene, GATA6. GATA6 
is implicated in human cancers as TSGs or oncogenes. In 
particular, loss-of-function GATA6 in human astrocytes 
may lead to the acceleration of tumorigenesis, suggesting 
its tumor suppressor role in astrocytoma [31]. Conversely, 
GATA6 overexpression could promote pancreatic 
carcinogenesis as an oncogene by activating the canonical 
Wnt signaling through antagonizing the expression 
of DKK1 at mRNA and protein level [32]. Indeed, 
recent studies showed that lncRNAs could regulate the 
expression of neighboring genes in cis or trans [25, 33]. 
For instance, ANRIL, an antisense transcript overlapping 
the INK4b/ARF/INK4a tumor suppressor locus, has been 
shown to repress its cognate transcript INK4b in cis 
through recruitment of polycomb repressive complex 1, 
and hence INK4b/ARF/INK4a repression [34]. The 
potential of molecular interaction between BM742401 and 
its neighboring GATA6 warrants further study.
Last but not least, an interesting observation was 
that methylation of BM742401, localized to chromosome 
18q11.2 was associated with that of miR-129-2 at 
chromosome 11q11.2 in CLL patients. Our previous study 
showed that miR-129-2, which targets sex determining 
region Y-box 4 (SOX4) and cyclin-dependent kinase 6 
(CDK6), was frequently methylated in CLL at diagnosis 
[11, 35, 36]. Therefore, concomitant frequent methylation 
of both BM742401 and miR-129-2 might collaborate to 
enhance cell proliferation and survival, and hence CLL 
leukemogenesis. Intriguingly, recent reports have suggested 
that lncRNAs could modulate their regulatory roles through 
potential interaction with miRNAs [37]. Therefore, a 
potential role of miR-129-2 in BM742401-associated tumor 
suppression in CLL warrants further studies.
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Taken together, this study was first report of 
BM742401 as a tumor suppressor lncRNA frequently 
methylated in CLL. Given the tumor suppressive role 
of BM742401 in CLL, the exact mechanism of tumor 
suppressive function of BM742401 warrant further studies.
MATERIALS AND METHODS
Patient samples
Bone marrow samples were obtained from 98 
Chinese CLL patients diagnosed according to the 
standard morphologic and immunophenotyping criteria 
as described [10, 38]. Patient details and demographic 
data have been reported in our previous study and were 
listed in Table 1 [13]. The median overall survival (OS) of 
this cohort was 89 months. The median OS of those with 
advanced and limited Rai stage were 57 and 111 months 
respectively (P = 0.006). Moreover, the median OS for 
those with and without high/intermediate-risk karyotype 
were 43 months and 111 months respectively (P = 0.04). 
Of these, methylation of miR-129-2 has been reported in 
51 patients previously [11]. This study was approved by 
the Institutional Review Board of Queen Mary Hospital 
and samples were collected with written informed consent 
and in accordance with the Declaration of Helsinki.
Cell lines and culture 
The human CLL cell lines MEC1 and CLL-
AAT were purchased from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen Deutsche GmbH 
(DSMZ) (Braunschweig, Germany) and American Type 
Culture Collection (ATCC) (Manassas, USA) respectively. 
MEC2 [39] I83-E95 [40] and WAC3CD5+ [40] were 
kindly provided by Dr John C. Byrd, Department of 
Medicine, Ohio State University. HG3 and 232B4 were 
established and kindly provided by Prof. Anders Rosén, 
Department of Clinical & Experimental Medicine, 
Linköping University [41, 42]. Cell cultures were 
maintained in 90% RPMI 1640 + 10% fetal bovine serum, 
supplemented with 50 U/ml penicillin and 50 µg/ml 
streptomycin (Invitrogen, Carlsbad, CA, USA) in a 
humidified atmosphere of 5% CO
2
 at 37°C.
Methylation-specific polymerase chain reaction 
(MSP)
DNA was extracted from 98 diagnostic marrow 
samples, seven CLL cell lines and nine healthy normal 
controls [buffy coats of peripheral blood (N = 3), bone 
marrow (N = 3), and CD19-sorted peripheral blood 
B-cells (N = 3)] by the QIAamp DNA Blood Mini Kit 
(QIAGEN, Germany). Bisulfite treatment of DNA was 
performed to convert unmethylated cytosine to uracil 
(but unaffecting methylated cytosine) using the EpiTect 
Bisulfite Kit kit (QIAGEN, Hilden, Germany). Each 
bisulfite-treated sample was amplified using primer sets 
specific to methylated DNA (methylated-MSP, M-MSP) 
and unmethylated DNA (unmethylated-MSP, U-MSP) 
respectively. Details of primers and conditions for M-MSP 
and U-MSP of BM742401 were given in Table 2.
Quantitative bisulfite pyrosequencing
Methylation-unbiased primers were designed 
by PSQ Assay Design software (Biotage) and used to 
amplify the promoter region of BM742401, encompassing 
the amplicon of MSP, in the bisulfite-treated DNA. 
Forward primer: 5′-AGGGGAGGAGAGAAAAGAG-3′; 
biotinylated reverse primer: 5′-AACTATACACTACCAAC 
TCCT-3′; condition: 2 mM/61°C/50X. A stretch of DNA 
with 7 consecutive CpG dinucleotides was pyrosequenced 
using sequencing primer: 5′-GTTTAGGTAGATAA 
TGAGAGT-3′.
5-Aza-2ʹ-deoxycytidine (5-AzadC) treatment
WAC3CD5+ cells at log-phase were cultured with 
0.5 µM of 5-AzadC (Sigma-Aldrich, St. Louis, MO, USA) 
for 5 days in a six-well plate at a density of 1 × 106 cells/ml. 
Fresh 5-AzadC was replaced every 24 hours. Cells treated 
with 5-AzadC on day 0 and day 5 were harvested for 
further analysis.
Plasmid construction and lentiviral transduction 
of BM742401
The full-length cDNA of BM742401 was amplified 
and cloned into the XbaI and EcoRI sites of a pCDH-
CMV-MCS-EF1-copGFP lentivector (System Biosciences; 
LV500A-1) (Table 2). The insert sequence was confirmed 
by direct sequencing (Figure 3A). According to the 
manufacturer’s instructions, the BM742401-containing 
construct and pPACK packaging plasmid mix were then 
co-transfected into 293TN cells, followed by collection of 
supernatant at 48 hours after transfection. The supernatant 
(200 μl) was added into WAC3CD5+ cells and cultured 
for 72 hours. GFP-positive WAC3CD5+ cells were 
selected by flow cytometry (BD FACSAria I Cell Sorter) 
and further cultured for two weeks. WAC3CD5+ cells 
transduced with GFP-expressing empty vector plasmid 
were used as negative control. 
Knockdown of BM742401 by antisense 
oligonucleotides (ASO)
BM742401-specific 2′-O-Methyl phosphorothioate 
antisense oligonucleotides (2′ OMe-PS ASOs) were 
designed, chemically synthesized and purchased from 
Integrated DNA Technologies (Coralville, IA, USA). ASO1 
(BM742401-2′OMe/PS-320): mG*mA*mA*mA*mA*G*
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A*A*C*C*A*A*A*A*G*mC*mA*mA*mG*mG; ASO2 
(BM742401-2′OMe/PS-96): mG*mG*mA*mG*mG*C* 
A*A*A*G*T*G*G*A*A*mC*mG*mU*mA*mA; non- 
targeting ASO control: mG*mC*mG*mU*mA*T*T*A*T* 
A*G*C*C*G*A*mU*mU*mA*mA*mC. Knockdown of 
BM742401 was performed in 232B4 cells, which were 
plated at a density of 1 × 106/ml in a 12-well plate and 
transfected with BM742401-ASO1, BM742401-ASO2 
or non-targeting control ASO at a final concentration of 
10nM using Lipofectamine 2000 (Invitrogen), according 
to the manufacturer’s instructions. Cells were cultured and 
analyzed at 48 hours after transfection. The efficiency of 
knockdown was determined by qRT-PCR of BM742401.
Quantification of BM742401
Total RNA was extracted by mirVana miRNA 
Isolation Kit (Ambion, Austin, TX, USA) and reverse 
transcribed by QuantiTect Reverse Transcription Kit 
(QIAGEN, Valencia, CA). BM742401 was quantified 
using SYBR Green Master Mix (ABI, Foster City, 
CA, USA), following the manufacturer’s instructions. 
The 2-∆∆CT method was used to detect the expression of 
BM742401 before and after BM742401 over-expression 
(or 5-AzadC treatment) in WAC3CD5+ cells [43]. The 
∆CT method is used for comparing the BM742401 
expression between methylated and unmethylated CLL 
cell lines. GAPDH was used as endogenous control for 
data analysis of BM742401. Primers and conditions used 
for detection of BM742401 were summarized in Table 2.
MTT assay, Trypan blue dye exclusion assay and 
cell cycle analyses
The tumor suppressor function of BM742401 was 
studied by MTT and Trypan blue dye exclusion assay. 
In brief, cells from each stably transduced sample were 
seeded in a 96-well microtitre plate at 2 × 105 cells/well 
in 100 µl of medium. After 72 hours, each well was 
added 10 µl of 5 mg/ml MTT reagent (Sigma-Aldrich) 
and incubated for four hours. Then each well was added 
with 100 µl dimethyl sulfoxide (DMSO), followed by 
the measurement of absorbance at 550 nm with reference 
to 650 nm. The percentage of dead cells was measured 
by Trypan blue dye exclusion assay under microscope. 
Five random microscopic fields were counted for each 
Table 1: Demographic data of the 98 CLL patients at diagnosis
Characteristic Value
Gender
Male 67 (68.4%)
Female 31 (31.6%)
Age 
Median 67
Range 37–91
Rai stage‡
Limited Stage (stage 0/I/II) 56 (62.2%)
Advanced Stage (stage III/IV) 34 (37.8%)
Lymphocyte count
Median 16 × 109/L
Range 10–540 × 109/L
High-risk cytogenetics*
del(17p) 3 (4.8%)
del(11q) 2 (3.2%)
trisomy 12 11 (17.7%)
Low-risk cytogenetics*
del(13) 19 (30.6%)
normal karyotype 20 (32.4%)
Other karyotype abnormalities 7 (11.3%)
‡, from 90 patients with clinical data; *, from 62 patients with cytogenetic data.
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sample. Dead cells (%) = (total number of dead cells per 
microscopic field / total number of cells per microscopic 
field) × 100. Cell cycle analysis was conducted by 
propidium iodide (PI) staining. Briefly, cells were 
washed in phosphate buffered saline (PBS), fixed in cold 
70% ethanol at 4°C overnight, washed twice in PBS, 
resuspended and then incubated in 50 μg/ml PI staining 
solution with 5 μg/ml RNase A at 4°C for at least 2 hours, 
followed by the analyze of flow cytometry (Beckman 
Coulter Cytomics FC 500). Each sample was done in 
duplicate. MTT assay and Trypan blue dye exclusion assay 
were performed in triplicates of each sample. Data were 
plotted by mean ± standard deviation and compared by 
Student’s t-test.
Treatment with Caspase 9 inhibitor
WAC3CD5+ cells transduced with GFP-expressing 
empty vector or BM742401 vector were treated with 
10 µM Z-LEHD-FMK (Caspase 9 inhibitor, R&D system) 
for 3 days in a 12-well plate at a density of 1 × 106 cells/ml 
respectively. After 72 hours, empty or BM742401 vector 
cells with or without treatment were harvested for Trypan 
Blue exclusive assay.
Western blotting 
Seventy-two hours after equal number of cells 
(2 × 106) from stably transduced samples were seeded 
in a six-well plate, total proteins (20 μg) were isolated 
at for Western Blot analysis, as described [10]. The 
primary antibodies incubated at 4°C overnight were 
anti-Caspase 3 (1:1000; Cell Signaling), -Caspase 
8 (1:1000; Cell Signaling), -Caspase 9 (1:1000; Cell 
Signaling) and anti-actin (1:5000; Sigma-Aldrich, USA), 
followed by incubation with anti-rabbit or anti-mouse 
horseradish peroxidase conjugate secondary antibody 
at room temperature for 1 hour. ECL plus Western 
blotting detection reagent was used for the detection of 
protein signals with X-ray film (Amersham Biosciences, 
Buckinghamshire, UK). Protein bands were quantified 
using densitometry as measured by Quantity One 4.6.2 
software (Bio-Rad); hence relative protein expression was 
expressed in comparison to corresponding control.
Statistical analysis  
In 98 primary CLL samples, the correlation between 
BM742401 methylation with continuous (mean age, mean 
lymphocyte counts, diagnostic hemoglobin or platelet 
counts) and categorical variables (gender, Rai stage or 
high-risk karyotypes) were analyzed by student’s t-test 
and chi-square test (or Fisher’s exact test) respectively. 
OS is measured from the date of diagnosis to the date 
of last follow-up or death. Survival was plotted by the 
Kaplan-Meier method and compared by the log-rank 
test. OS of CLL patients with limited Rai stage (stage 
0/I/II) was compared with those with advanced Rai 
stage (stage III/IV). Moreover, OS of CLL patients with 
high-risk karyotypes [del(17p), del(11q) or trisomy 12] 
was compared to those with standard-risk karyotypes 
[del(13q), normal karyotype or other karyotypic changes]. 
Table 2: Primer sequences and reaction condition
Gene  Forward primer (5′ to 3′) Reverse primer (5′ to 3′) Tm/cycles/MgCl
2
   References
(I) Methylation-specific PCR (MSP)
BM742401
U-MSP
TGTGTTGTTTAGGTAGATAAT 
GAGAGTTGT
CCAAATCAAACATTCT 
ATAACCTCCA
60°C/35 × /2 mM
M-MSP CGTTTAGGTAGATAATGAGA 
GTCGC
AAATCAAACGTTCTAT 
AACCTCCG
62°C/35 × /1.5 mM
(II)  Reverse transcription-polymerase chain reaction (RT-PCR)
BM742401 TTGCTACCGAGAAGGTCCAG GACATCCTTGTAGAAA 
AGAACCAA
60°C/40×  [24]  
GAPDH ACCACAGTCCATGCCATCACT TCCACCACCCTGTTG 
CTGTA
60°C/40×  [44]
(III)  Cloning PCR
BM742401 GCTCTAGACATTCTTCGTTG 
TAAATTGCTTCTAA
GCTCTAGACGGAATTC 
AAAAGGAGCAATCAC 
TTATTTTTCC
56°C/40 × /2 mM
Abbreviations: M-MSP, MSP for the methylated allele; U-MSP, MSP for the unmethylated allele; Tm, annealing temperature.
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Association between methylation of BM742401 and miR-
129-2 was studied by chi-square test. All P values were 
two-sided. 
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